Granulocyte-colony-stimulating factor after allogeneic and autologous bone marrow transplantation in children

✍ Scribed by Saarinen, Ulla M. ;Hovi, Liisa ;Juvonen, Eeva ;Riikonen, Pekka ;Möttönen, Merja ;Mäkipernaa, Anne

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 685 KB
• Volume: 26
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/(sici)1096-911x(199606)26:6<380::aid-mpo2>3.0.co;2-d

✦ Synopsis

We evaluated the use of granulocyte CSF (G-CSF) after both allogeneic BMT (allo-BMT) and autologous BMT (ABMT) in children. After allo-BMT, G-CSF was used in 15 children who were compared with 20 historical controls. The ABMT patients were two sequential groups: the G-CSF group of 13 children and 11 historical controls. The patients were conditioned with different highdose chemotherapy regimens with or without total body irradiation. G-CSF was administered at 5 pg/kg/day S.C. and was continued until an absolute neutrophil count (ANC) of 1,000 x 10' 11 was reached. Following allo-BMT, G-C6F accelerated myeloid engraftment with a difference of 5 days at the ANC level of 500 x 10611 ( P < 0.02) and 9 days at 1,000 x 10' /1 ( P < 0.001). In the ABMT patients, G-CSF also accelerated myeloid engraftment. The difference between the G-CSF group and the control group was 6 days at ANC 200 (P < 0.05), 11 days at ANC 500 ( P < 0.02), and 17 days at ANC 1,000 (P < 0.005). In the ABMT patients, benefit by G-CSF was also observed in a smaller number of days with fever and days on antibiotics. We conclude that G-CSG 'significantly accelerated myeloid engraftment, after both allogeneic and autologous BMT in children, and also decreased the duration of febrile illness in the ABMT patients.